Verifying…
Home / Drug A–Z / MC Foris Prednisolone 5 mg Tablets

MC Foris Prednisolone 5 mg Tablets

NAFDAC Reg. No. A4-9597 · Drug

Registered with NAFDAC. Registration activeAs of 28 October 2026 · synced automatically from official sources.
Product
MC Foris Prednisolone 5 mg Tablets
NAFDAC number
A4-9597
Active ingredient
Prednisolone
Strength
5 mg
Form
Tablet
Pack size
10 x 10's
Manufacturer
Not listed
Applicant (holder)
MC Foris Pharmaceuticals Limited
Approved
25 Feb 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
24 Feb 2026
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • MC Foris Prednisolone 5 mg Tablets is on the NAFDAC register with an active registration (A4-9597). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use MC Foris Prednisolone 5 mg Tablets

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Who it is for

1. Endocrine disorders . Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders . …

How to take it and how often
  • The initial dosage of prednisolone tablets may vary from 5 mg to 60 mg per day depending on the specific disease entity being treated
  • In situations of less severity, lower doses will generally suffice, while in selected patients higher initial doses may be required
  • The initial dosage should be maintained or adjusted until a satisfactory response is noted
  • If after a reasonable period of time there is a lack of satisfactory clinical response, prednisolone should be discontinued and the patient transferred to other appropriate therapy
  • IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT
  • After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small increments at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached
  • It should be kept in mind that constant monitoring is needed in regard to drug dosage
  • Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisolone for a period of time consistent with the patient’s condition. …
While you are taking it
  • Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles
  • Patients should also be advised that if they are exposed, medical advice should be sought without delay
  • Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage
  • This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted
  • Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. …
Talk to a doctor first if

Systemic fungal infections

Warnings

In patients on corticosteroid therapy subjected to unusual stress increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including prednisolone, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. …

Possible side effects

Fluid and Electrolyte Disturbances Sodium retention. Fluid retention. Congestive heart failure in susceptible patients. Potassium loss. Hypokalemic alkalosis. Hypertension. Musculoskeletal Muscle weakness. Steroid myopathy. Loss of muscle mass. Osteoporosis. Vertebral compression fractures. Aseptic necrosis of femoral and humeral heads. Pathologic fracture of long bones. Gastrointestinal Peptic ulcer with possible perforation and hemorrhage. Pancreatitis. Abdominal distention. Ulcerative esophagitis. Dermatologic Impaired wound healing. Thin fragile skin. Petechiae and ecchymoses. Facial erythema. Increased sweating. May suppress reactions to skin tests. Neurological Convulsions. …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2024-02-16.

Label for MC Foris Prednisolone 5 mg Tablets, the active ingredient registered with NAFDAC.

Check your pack of MC Foris Prednisolone 5 mg Tablets

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC · WHO · U.S. FDA · Health Canada · NLM

About MC Foris Prednisolone 5 mg Tablets

What is in MC Foris Prednisolone 5 mg Tablets?

MC Foris Prednisolone 5 mg Tablets contains Prednisolone (5 mg), as tablet, according to its NAFDAC registration record.

Is MC Foris Prednisolone 5 mg Tablets registered with NAFDAC?

Yes. MC Foris Prednisolone 5 mg Tablets is listed on the NAFDAC register under registration number A4-9597, and its registration is active as of 28 October 2026.

Has MC Foris Prednisolone 5 mg Tablets been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches MC Foris Prednisolone 5 mg Tablets in our automatically synced alert list.

How can I check that my pack of MC Foris Prednisolone 5 mg Tablets is genuine?

Run a free authenticity scan with the NAFDAC number A4-9597, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take MC Foris Prednisolone 5 mg Tablets?

Follow your prescription or the leaflet in your pack. The official label says: The initial dosage of prednisolone tablets may vary from 5 mg to 60 mg per day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice, while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonabl…

What is MC Foris Prednisolone 5 mg Tablets used for?

1. Endocrine disorders . Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disor (Summarised from the official U.S. FDA label for MC Foris Prednisolone 5 mg Tablets. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used MC Foris Prednisolone 5 mg Tablets? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.